GlassScriptPhysician profile
Alisha Marie Morris
NPI 1558806646
$8,079.12
in general payments reported to CMS, 2019-2025
57 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $1,207 · 2023: $2,702 · 2024: $1,632 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,628 · Travel and Lodging: $745 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,627.98 |
| Travel and Lodging | $744.77 |
| Education | $159.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,158.73 | 2022-2024 | Intellis Adaptivestim, Synchromedii |
| Astrazeneca Pharmaceuticals LP | $844.60 | 2021-2025 | Breztri, Fasenra, Tezspire |
| Abbvie INC. | $827.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $377.55 | 2022-2024 | Relistor |
| Regeneron Healthcare Solutions, INC. | $349.08 | 2024-2025 | Dupixent |
| Vertos Medical, INC. | $340.52 | 2022-2024 | Mild Device Kit |
| Glaxosmithkline, LLC. | $309.47 | 2024-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $294.26 | 2021-2025 | Tezspire |
| Abbott Laboratories | $268.69 | 2024 | Proclaim, Assurity |
| Takeda Pharmaceuticals U.S.A., INC. | $136.94 | 2024-2025 | Cuvitru, Glassia, Takhzyro |
| Lilly USA, LLC | $133.35 | 2021-2024 | Emgality |
| Otsuka America Pharmaceutical, INC. | $131.22 | 2025 | Rexulti |
| Almatica Pharma LLC | $122.84 | 2022-2023 | Gralise |
| Ferring Pharmaceuticals INC. | $113.63 | 2022-2024 | Euflexxa |
| Edwards Lifesciences Corporation | $105.48 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $101.49 | 2025 | |
| Inari Medical, INC. | $94.73 | 2021 | |
| Boston Scientific Corporation | $94.38 | 2022-2023 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Tersera Therapeutics LLC | $86.74 | 2023-2024 | Prialt |
| Spr Therapeutics, INC | $78.79 | 2022-2024 | Sprint Pns System |
| Csl Behring | $74.96 | 2024-2025 | Kcentra, Haegarda |
| Biocryst US Sales Co., LLC | $62.11 | 2024-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.08 | 2025 | Jascayd |
| Electromed, INC. | $55.04 | 2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $51.39 | 2025 | |
| Pfizer INC. | $42.21 | 2023-2024 | |
| United Therapeutics Corporation | $42.07 | 2025 | Tyvaso |
| Hikma Pharmaceuticals USA | $39.97 | 2024-2025 | Ryaltris |
| Insmed, INC. | $39.71 | 2025 | Brinsupri, Arikayce |
| Pulmonx Corporation | $39.63 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Mallinckrodt Hospital Products INC. | $37.56 | 2025 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $36.77 | 2022 | |
| Nalu Medical, INC. | $34.92 | 2023-2024 | Nalu Neurostimulation System |
| Curonix LLC | $34.78 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Biohaven Pharmaceuticals, INC. | $34.07 | 2021 | |
| Protega Pharmaceutials INC | $29.57 | 2023 | Roxybond |
| Forte Bio-Pharma LLC | $27.70 | 2024 | Prolate, Nalocet |
| Lundbeck LLC | $26.93 | 2023 | Vyepti |
| Viatris Specialty LLC | $26.71 | 2025 | Yupelri |
| Azurity Pharmaceuticals, INC. | $24.49 | 2023 | Horizant |
| Axsome Therapeutics, INC. | $24.39 | 2025 | Sunosi |
| Si-Bone, INC. | $23.24 | 2023 | |
| Relievant Medsystems, INC. | $22.55 | 2023 | Intracept |
| Novo Nordisk INC | $21.01 | 2021 | |
| Orthogenrx INC. | $19.70 | 2021 | |
| Valinor Pharma, LLC | $18.52 | 2024 | Movantik |
| Idorsia Pharmaceuticals US INC | $17.40 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $15.71 | 2023 | Lyvispah |
| Actelion Pharmaceuticals US, INC. | $15.49 | 2025 | Opsumit |
| Novartis Pharmaceuticals Corporation | $15.10 | 2025 | |
| Ani Pharmaceuticals, INC. | $14.85 | 2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $14.63 | 2025 | |
| Optinose US, INC. | $14.27 | 2024 | |
| Inspire Medical Systems, INC. | $14.15 | 2025 | Inspire |
| Adlon Therapeutics L.P. | $13.74 | 2021 | |
| Genentech USA, INC. | $13.53 | 2023 | Tecentriq |
| Stemline Therapeutics INC. | $12.73 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.